Literature DB >> 31723850

EHA Guidance Document The process of CAR-T cell therapy in Europe.

.   

Abstract

Year:  2019        PMID： 31723850      PMCID： PMC6745926          DOI： 10.1097/HS9.0000000000000280

Source DB:  PubMed          Journal:  Hemasphere        ISSN： 2572-9241


× No keyword cloud information.
  5 in total

1.  Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective.

Authors:  María Belen Marzal-Alfaro; Vicente Escudero-Vilaplana; Jose Luis Revuelta-Herrero; Roberto Collado-Borrell; Ana Herranz-Alonso; Maria Sanjurjo-Saez
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

2.  Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.

Authors:  Vera Rentsch; Katja Seipel; Yara Banz; Gertrud Wiedemann; Naomi Porret; Ulrike Bacher; Thomas Pabst
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

3.  Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

Authors:  Martin Hutchings; Franck Morschhauser; Gloria Iacoboni; Carmelo Carlo-Stella; Fritz C Offner; Anna Sureda; Gilles Salles; Joaquín Martínez-Lopez; Michael Crump; Denise N Thomas; Peter N Morcos; Cristiano Ferlini; Ann-Marie E Bröske; Anton Belousov; Marina Bacac; Natalie Dimier; David J Carlile; Linda Lundberg; David Perez-Callejo; Pablo Umaña; Tom Moore; Martin Weisser; Michael J Dickinson
Journal:  J Clin Oncol       Date:  2021-03-19       Impact factor: 50.717

Review 4.  A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.

Authors:  N Zozaya; J Villaseca; F Abdalla; M A Calleja; J L Díez-Martín; J Estévez; R García-Sanz; J Martínez-López; J Sierra; R Vera; A Hidalgo-Vega
Journal:  Clin Transl Oncol       Date:  2022-01-08       Impact factor: 3.340

5.  GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18.

Authors:  Wolfgang Glienke; Anna Christina Dragon; Katharina Zimmermann; Alexandra Martyniszyn-Eiben; Mira Mertens; Hinrich Abken; Claudia Rossig; Bianca Altvater; Krasimira Aleksandrova; Lubomir Arseniev; Christina Kloth; Andriana Stamopoulou; Thomas Moritz; Holger N Lode; Nikolai Siebert; Rainer Blasczyk; Lilia Goudeva; Axel Schambach; Ulrike Köhl; Britta Eiz-Vesper; Ruth Esser
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.